Cargando…

Correction: Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era

Detalles Bibliográficos
Autores principales:	Giustina, Andrea, Legg, Ewen, Cesana, Bruno Mario, Frara, Stefano, Mortini, Pietro, Fleseriu, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093915/ https://www.ncbi.nlm.nih.gov/pubmed/33945074 http://dx.doi.org/10.1007/s12020-021-02720-2

Ejemplares similares

Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era
por: Giustina, Andrea, et al.
Publicado: (2021)

OR32-6 Pre-Surgical GH Levels Predict the Risk of Morphometric Vertebral Fracture, Which Is an Early and Frequent Event in the Natural History of Acromegaly
por: Frara, Stefano, et al.
Publicado: (2019)

MON-LB50 Poor Response to Pre-Surgical Treatment With Somatostatin Receptor Ligands Is Associated With Diabetes Mellitus in Patients With Acromegaly
por: Frara, Stefano, et al.
Publicado: (2020)

COVID-19 and hypopituitarism
por: Frara, Stefano, et al.
Publicado: (2021)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

Results of Gamma Knife Radiosurgery in Acromegaly
por: Franzin, Alberto, et al.
Publicado: (2012)

Correction to: Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
por: Labadzhyan, Artak, et al.
Publicado: (2021)

High Prevalence of Radiological Vertebral Fractures in Patients With TSH-Secreting Pituitary Adenoma
por: Frara, Stefano, et al.
Publicado: (2018)

Updates in Diagnosis and Treatment of Acromegaly
por: Zahr, Roula, et al.
Publicado: (2018)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Updates in rare and not-so-rare complications of acromegaly: focus on respiratory function and quality of life in acromegaly
por: Langlois, Fabienne, et al.
Publicado: (2020)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

A Pituitary Society update to acromegaly management guidelines
por: Fleseriu, Maria, et al.
Publicado: (2020)

Correction to: Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study
por: Caron, Philippe, et al.
Publicado: (2018)

Individualized acromegaly treatment: Is stereotactic radiation therapy changing the paradigm?
por: Liu, Winnie, et al.
Publicado: (2022)

Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
por: Fleseriu, Maria
Publicado: (2010)

The Pharmacological Burden of Comorbidities in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2021)

The emerging osteo-metabolic phenotype of COVID-19: clinical and pathophysiological aspects
por: di Filippo, Luigi, et al.
Publicado: (2021)

Durable biochemical response and safety with oral octreotide capsules in acromegaly
por: Samson, Susan L, et al.
Publicado: (2022)

Correction: Surgeons’ perspectives on artificial intelligence to support clinical decision-making in trauma and emergency contexts: results from an international survey
por: Cobianchi, Lorenzo, et al.
Publicado: (2023)

Safety and tolerability of pasireotide long-acting release in acromegaly—results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study
por: Fleseriu, Maria, et al.
Publicado: (2016)

Pegvisomant in acromegaly: an update
por: Giustina, A., et al.
Publicado: (2017)

An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies
por: Fleseriu, Maria, et al.
Publicado: (2020)

Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Correction to: Team dynamics in emergency surgery teams: results from a first international survey
por: Cobianchi, Lorenzo, et al.
Publicado: (2021)

Correction: A microbial survey of the International Space Station (ISS)
por: Lang, Jenna M., et al.
Publicado: (2018)

Correction to: Endocrine and metabolic aspects of the COVID-19 pandemic
por: Marazuela, Mónica, et al.
Publicado: (2021)

Hypocalcemia in COVID-19: Prevalence, clinical significance and therapeutic implications
por: di Filippo, Luigi, et al.
Publicado: (2021)

Pituitary tumor centers of excellence for Cushing’s disease
por: Couselo, Marcos, et al.
Publicado: (2022)

The osteo-metabolic phenotype of COVID-19: an update
por: di Filippo, Luigi, et al.
Publicado: (2022)

Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
por: Giustina, Andrea, et al.
Publicado: (2012)

Correction to: Restricted working hours in Austrian residency programs: Survey results
por: Bergmeister, Konstantin D., et al.
Publicado: (2018)

Vitamin D in the Covid-19 era: a review with recommendations from a G.I.O.S.E.G. expert panel
por: Ulivieri, Fabio Massimo, et al.
Publicado: (2021)

Correction to: Co-Creation of a Lanreotide Autogel/Depot Syringe for the Treatment of Acromegaly and Neuroendocrine Tumours Through Collaborative Human Factor Studies
por: Adelman, Daphne T., et al.
Publicado: (2020)

The Endothelium in Acromegaly
por: Maffei, Pietro, et al.
Publicado: (2019)

Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database
por: Petrossians, Patrick, et al.
Publicado: (2017)

MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

A consensus on the diagnosis and treatment of acromegaly complications
por: Melmed, S., et al.
Publicado: (2012)

PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial
por: Elenkova, Atanaska, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_irtboibjack8lnf4s25ppdn47j